Skip to main content
. 2019 Mar 5;19:227. doi: 10.1186/s12879-019-3833-6

Fig. 2.

Fig. 2

PCV13 Trial Simulated in 3 + 1 Vaccinated Population. a VT carriage prevalence in all four trial arms. Lines represent average VT prevalence across 50 simulations while shading is bounded by one standard deviation. b The difference in VT prevalence between the 3 + 1 and 2 + 1 trial arms (averaged across 50 simulations) graphed over time. c The difference in VT prevalence between the 3 + 1 and 1 + 1 trial arms (averaged across 50 simulations) graphed over time. The zero difference line is shown in red. Note the scale of the y-axis